PIN64 Assessing the Cost-Effectiveness (CE) of Vaccinating the Elderly and At-Risk Adults With the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) or No Vaccination (NoVac) in the UK
Value in Health - United Kingdom
doi 10.1016/j.jval.2012.08.1131
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2012
Authors
Publisher
Elsevier BV